...expression of SSTR2 and SSTR5 in GEP-NEN and investigated the efficacy and safety of octreotide long-acting release (LAR) in the treatment of advanced gastroenteropancreatic neuroendocrine tumors (GEP-NET)...Kaplan-Meier survival curves revealed that the median OS time of patients with positive expression of SSTR2 was not reached (NR), while patients with negative expression had a median OS of 3.48 years, which demonstrated a statistically significant difference (χ2=8.758, P=0.003)...All 54 patients that received octreotide LAR were followed up for a period of 3.2–164.5 months, with a median follow-up period of 31.8 months...three patients achieved partial remission (PR), with the ORR being 5.6% (95% CI, 0.0–11.7%). A total of 43 patients achieved SD, with the SD rate being 79.6% (95% CI, 68.9–90.4%) and 8 patients demonstrated PD. At the conclusion of follow-up, there were still three patients achieving PR, 26 patients achieving SD and 25 patients demonstrating PD.